---
title: "new"
date: "2023-09-24 02:06:00"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[test content]]

<!-- _header: "Outline" -->

- [wow testmy tilte](#wow-testmy-tilte)
  - [test](#test)

<!-- _footer: "" -->

---

> [!NOTE]
> **A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism**
> TLDR: [[LitNote/rosellClinicalPracticebasedEvaluation2019.md|Rosell. (2019)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$rosellClinicalPracticebasedEvaluation2019)
> CiteKeyğŸ”‘: [@rosellClinicalPracticebasedEvaluation2019]

> [!NOTE]
> **A Case of Elevated Intracranial Pressure Diagnosed With Point-of-Care Ocular Ultrasound**
> TLDR: [[LitNote/heinicke_case_2020.md|Heinicke. (2020)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$heinicke_case_2020)
> CiteKeyğŸ”‘: [@heinicke_case_2020]

> [!NOTE]
> **A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.**
> TLDR: [[LitNote/ngCommonBIMDeletion2012.md|Ng. (2012)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$ngCommonBIMDeletion2012)
> CiteKeyğŸ”‘: [@ngCommonBIMDeletion2012]

> [!NOTE]
> **2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline**
> TLDR: [[LitNote/smith_2006_2006.md|Smith. (2006)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$smith_2006_2006)
> CiteKeyğŸ”‘: [@smith_2006_2006]

> [!NOTE]
> **5-Fluorouracil: mechanisms of action and clinical strategies**
> TLDR: [[LitNote/l5FluorouracilMechanismsAction2003.md|L. (2003)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$l5FluorouracilMechanismsAction2003)
> CiteKeyğŸ”‘: [@l5FluorouracilMechanismsAction2003]

> [!NOTE]
> **Regulation of B-cell fate by antigen-receptor signals**
> TLDR: [[LitNote/niiroRegulationBcellFate2002.md|Niiro. (2002)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@$niiroRegulationBcellFate2002)
> CiteKeyğŸ”‘: [@niiroRegulationBcellFate2002]


> [!NOTE]
> **Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial**
> TLDR: [[LitNote/finn_pembrolizumab_2020.md|Finn. (2020)]]
> Zotero ğŸ“š: [Item](zotero://select/items/@finn_pembrolizumab_2020)
> CiteKeyğŸ”‘: [@finn_pembrolizumab_2020]
